We hypothesize that CTC analysis might be transformative and provide an exceptional tool to identify up-to-date drug sensitivity patterns in individual patients, both in the adjuvant setting as well as in cases with advanced metastatic disease that is refractory to standard of care treatments. Based on this hypothesis, our goal is to develop a novel CTC-based microfluidic tool for capturing CTCs and assessing their drug sensitivities, to support clinical decision-making.